| [1] |
DeMarzo AM, Coffey DS, Nelson WG. New concepts in tissuespecificity for prostate cancer and benign prostatic hyperplasia.Urology 1999;53: 29-39.
|
| [2] |
Coffey DS. Similarities of prostate and breast cancer: evolution,diet and estrogens. Urology 2001; 57:31-8.
|
| [3] |
Coffey DS, Walsh PC. Clinical and experimental studies of benignprostatic hyperplasia.Urol Clin North Am 1990; 17: 461-75.
|
| [4] |
Prins GS, Jung MH, Vellanoweth RL, Chatterjee B, Roy AK. Agedependentexpression of the androgen receptor gene in the prostateand its implication in glandular differentiation and hyperplasia. DevGenet 1996;18: 99-106.
|
| [5] |
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG,et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer2007; 7: 256-69.
|
| [6] |
Jäämaa S, Laiho M. Maintenance of genomic integrity after DNAdouble strand breaks in the human prostate and seminal vesicleepithelium: the best and the worst. Mol Oncol 2012; 6: 473-83.
|
| [7] |
Stoeckle MY, Hebert PD. Barcode of life. Sci Am 2008; 299: 82-6.
|
| [8] |
Gleick J. The information. New York, NY: Pantheon Books, 2011.
|
| [9] |
Scott TA, Arnold R, Petros JA. Mitochondrial cytochrome c oxidasesubunit 1 sequence variation in prostate cancer. Scientifica (Cairo)2012; 2012: 701810.
|
| [10] |
Gann PH, Deaton R, Amatya A, Mohnani M, Rueter EE, Yang Y,et al. Development of a nuclear morphometic signature for prostatecancer risk in negative biopsies.PLoS One 2013; 8: e9457.
|
| [11] |
Veltri RW, Christudass CS.Nuclear morphometry, epigenetic changesand clinical relevance in prostate cancer. Adv Exp Med Biol 2014;773:77-99.
|
| [12] |
Bista RK, Wang P, Bhargava R, Uttam S, Hartman DJ, Brand RE, etal. Nuclear nano-morphology markers of histologically normal cellsdetect the “field effect” of breast cancer. Breast Cancer Res Treat2012;135: 115-24.
|
| [13] |
Benson MC, Walsh PC. The application of flow cytometry to theassessment of tumor cell heterogeneity and the grading of humanprostatic cancer: preliminary results. J Urol 1986; 135: 1194-8.
|
| [14] |
Lowes LE, Goodale D, Keeney M, Allan AL. Image cytometryanalysis of circulating tumor cells. Methods Cell Biol 2011; 102:261-90.
|
| [15] |
Yang X, Shi C, Toing R, Qian W, Zhau HE, Want R, et al. Near IRheptamethine cyanine dye-mediated cancer imaging. Clin CancerRes 2010; 16:2833-44.
|
| [16] |
Yang X, Shao C, Wang R, Chu CY, Hu P, Master V, et al. Opticalimaging of kidney cancer with novel near infrared heptamethinecarbocyanine fluorescent dyes. J Urol 2013;189:702-10.
|
| [17] |
Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Brüggeman H,Nelson WG, et al. A mouse model of chronic prostatic inflammationusing a human prostate cancer-derived isolate of Propionibacteriumacnes. Prostate 2013; 73:1007-15.
|
| [18] |
Nelson WG, DeMarzo AM, Yegnasubramanian S. The diet as acause of human prostate cancer. Cancer Treat Res 2014; 159: 51-68.
|
| [19] |
Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS,Ewing LL. Soy of dietary source play a preventive role againstthe pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol1992; 43: 557-64.
|
| [20] |
Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, ZeiselSH, Willett WC, et al. Choline intake and risk of lethal prostatecancer: incidence and survival. Am J Clin Nutr 2012; 96: 855-63.
|
| [21] |
Nakai Y, Nelson WG, De Marzo AM. The dietary charred meatcarcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine actsas both a tumor initiator and promoter in the rat ventral prostate.Cancer Res 2007; 67: 1378-84.
|
| [22] |
Coffey DS. Self-organization, complexity and chaos: the newbiology for medicine. Nat Med 1998; 4:882-5.
|
| [23] |
Chu GC, Chung LW. RANK-mediated signaling network and cancermetastasis. Cancer Metastasis Rev 2014; 33(2-3): 497-509.
|
| [24] |
Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H,et al. Large oncosomes mediate intercellular transfer of functionalmicroRNA. Cell Cycle 2013; 12: 3526-36.
|
| [25] |
Camacho DF, Pienta KJ. Disrupting the networks of cancer. ClinCancer Res 2012; 18: 2801-8.
|
| [26] |
Camacho DF, Pienta KJ. A multi-targeted approach to treating bonemetastases. Cancer Metastasis Rev 2014; 33(2-3): 545-53.
|
| [27] |
Ben-Jacob E, Coffey DS, Levine H. Bacterial survival strategiessuggest rethinking cancer cooperativity. Trends Microbiol 2012;20: 403-10.
|
| [28] |
Lu M, Jolly MK, Levine H, Onuchic JN, Ben-Jacob E. Micro-RNA based regulation of epithelial-hybrid-mesenchymal fatedetermination. Proc Natl Acad Sci USA 2013; 110: 18144-9.
|
| [29] |
Schmidt LJ,Tindall DJ. Androgen recetor: past, present and future.Curr Drug Targets 2013; 14: 401-7.
|
| [30] |
Coffey DS, Shimazaki J, Williams-Ashman HG. Polymerizationof deoxyribonucleotides in relation to androgen-induced prostaticgrowth. Arch Biochem Biophys 1968; 124: 184-98.
|
| [31] |
Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS. Highmobility group protein I(Y): a candidate architectural protein forchromosomal rearrangements in prostate cancer cells. Cancer Res2002; 62: 647-51.
|
| [32] |
Getzenberg RG, Coffey DS.Changing the energy habitat of thecancer cell in order to impact therapeutic resistance. Mol Pharm2011; 8: 2089-93.
|
| [33] |
Garcia-Schurmann M, Coffey DS. The concept of evolution in thepathogenesis and treatment of prostate cancer. Br J Urol 1997; 79Suppl. 2: 9-17.
|
| [34] |
Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification andcharacterization of nuclease-stabilized RNA molecules that bindhuman prostate cancer cells via the prostate-specific membraneantigen. Cancer Res 2002; 62: 4029-33.
|
| [35] |
Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acidaptamers: clinical applications and promising new horizons. CurrMed Chem 2011; 18: 4206-14.
|
| [36] |
Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, etal. Prostate-targeted radiosensitization via aptamer-shRNA chimerasin human tumor xenografts. J Clin Invest 2011; 121: 2383-90.
|
| [37] |
Coffey DS. The real final exam. Prostate 1999; 39: 323-5.
|
